Atlas Trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Clinical trial NCT05145179 · UNKNOWN

Trial details

NCT number
NCT05145179
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Receptor, ErbB-2
Start date
2021-12-01
Primary completion
2023-12-01
Enrollment
162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.